Exicure, Inc.
XCURHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Exicure, Inc. focuses on Biotechnology services and products. Exicure, Inc. does not have significant operations. Valued at $12.3M, XCUR is a micro-cap name in its sector. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets.
Market Cap
$12.3M
Beta
3.60
P/E (TTM)
—
P/E (Fwd)
-2.51
EPS (TTM)
$-1.57
EPS (Fwd)
$-0.77
ROE
-145.2%
ROA
-32.5%
Cash
$2.6M
Total Debt
$22,000
Free CF
-$3.9M
52W Change
-75.7%
Annual Financials
Cash vs Debt
Where XCUR stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, XCUR finished 57.00% below its 150-day moving average ($4.00) and 58.15% below its 200-day moving average ($4.11). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is XCUR overbought or oversold?
At the July 15, 2026 close, XCUR's RSI(14) was 20.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $2.6M in cash and $22K in debt, XCUR maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$3.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -145.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from -$483K to $0.
Exicure, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, XCUR has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Exicure, Inc.'s trajectory.